Fundai

Aburaihan Pharmaceutical Company (DABUR) income statement

Operating revenue through to net profit and earnings per share

Ticker
DABUR
Industry
Pharmaceuticals
Market
Tehran Stock Exchange

Latest periods

Latest 6-month periods, in million rials
ItemTo 1405/06/31To 1404/06/31To 1403/06/31To 1402/06/31To 1401/06/31To 1400/06/31
Operating revenue35,516,08217,308,3509,422,6566,576,9867,146,0074,792,702
Cost of operating revenue-10,593,107-8,176,268-5,580,752-3,921,741-3,165,963-2,400,132
Gross profit (loss)24,922,9759,132,0823,841,9042,655,2453,980,0442,392,570
Selling, general and administrative expenses-1,558,450-658,197-400,337-456,012-291,688-181,005
Other income41,072111,21433,65021,80939,69125,702
Other expenses-1,061,997-377,182-41,233-92,694-14,0640
Operating profit (loss)22,343,6008,207,9173,433,9842,128,3483,713,9832,237,267
Finance costs-1,329,397-1,723,237-1,157,054-920,625-603,398-470,471
Other non-operating income and expenses266,507-118,392-62,773-34,0935,842-756
Profit (loss) from continuing operations before tax21,280,7106,366,2882,214,1571,173,6303,116,4271,766,040
Current year tax-4,612,234-1,249,680-449,169-287,896-689,981-391,783
Net profit (loss) from continuing operations16,668,4765,116,6081,764,988885,7342,353,8511,374,257
Net profit (loss)16,668,4765,116,6081,764,988885,7342,353,8511,374,257
Basic earnings (loss) per share9,365 rials2,857 rials981 rials492 rials2,615 rials2,292 rials
Net earnings (loss) per share, rials9,261 rials2,843 rials981 rials493 rials2,616 rials2,291 rials
Capital1,800,0001,800,0001,800,0001,800,000900,000600,000

Reporting periods

92 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/06/31.